Biocon reports Q2FY25 revenue of Rs 3,623cr amid generics pressure
Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue of Rs 3,623 crore. This represented a ... Read More
Biocon joins forces with Tabuk Pharmaceuticals to bring GLP-1 diabetes drugs to Middle East
In a strategic move to tackle the growing diabetes crisis in the Middle East, Biocon Limited has announced a partnership with Tabuk Pharmaceutical Manufacturing Company. ... Read More
Biocon and Biomm ink exclusive deal to bring Semaglutide to Brazil
Biocon Limited (BSE code: 532523, NSE: BIOCON), a leader in global biopharmaceutical innovations, has announced a pivotal licensing and supply agreement with Brazil's Biomm S.A., ... Read More